This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Effect of Alphagan on Retinal Blood Flow Autoregulation and Motion Detection in Patients With Normal Pressure Glaucoma

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Louis Pasquale, MD, Massachusetts Eye and Ear Infirmary
ClinicalTrials.gov Identifier:
NCT01105065
First received: April 14, 2010
Last updated: March 31, 2017
Last verified: March 2017
Results First Received: December 7, 2014  
Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment;   Masking: None (Open Label);   Primary Purpose: Treatment
Condition: Glaucoma
Intervention: Drug: brimonidine 0.15%

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
46 participants enrolled but only 23 had retinal vascular dysregulation.

Reporting Groups
  Description
Patients With RVD

Patients who exhibited retinal vascular dysregulation at the initial visit. Intervention: brimonidine 0.15% three times per day for 8 weeks.

Alphagan (brimonidine) 0.15%: One drop in each eye three times a day for 8 weeks.


Participant Flow:   Overall Study
    Patients With RVD
STARTED   23 
COMPLETED   17 
NOT COMPLETED   6 
Adverse Event                5 
Technical Problems                1 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Patients With RVD

Patients who exhibited retinal vascular dysregulation at the initial visit. Intervention: brimonidine 0.15% three times per day for 8 weeks.

Alphagan (brimonidine) 0.15%: One drop in each eye three times a day for 8 weeks.


Baseline Measures
   Patients With RVD 
Overall Participants Analyzed 
[Units: Participants]
 23 
Age [1] 
[Units: Years]
Mean (Standard Deviation)
 57.1  (10.8) 
[1] age range: 35 years to 80 years
Sex: Female, Male 
[Units: Participants]
Count of Participants
 
Female      12  52.2% 
Male      11  47.8% 
Region of Enrollment 
[Units: Participants]
 
United States   23 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Presence of Retinal Blood Flow Autoregulation   [ Time Frame: 8 weeks ]

2.  Secondary:   Frequency Doubling Perimetry   [ Time Frame: 8 weeks ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: Louis R. Pasquale, MD
Organization: Massachusetts Eye and Ear Infirmary
phone: 617-573-4270
e-mail: Louis_Pasquale@meei.harvard.edu


Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: Louis Pasquale, MD, Massachusetts Eye and Ear Infirmary
ClinicalTrials.gov Identifier: NCT01105065     History of Changes
Other Study ID Numbers: 10-03-019 (75643)
Study First Received: April 14, 2010
Results First Received: December 7, 2014
Last Updated: March 31, 2017